AHL
VRTX icon

Abel Hall LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Abel Hall LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$522K Sell
1,050
-424
-29% -$188K 0.09% 227
2026
Q1 		$658K Buy
1,474
+114
+8% +$53.2K 0.14% 129
2025
Q4 		$617K Buy
+1,360
New +$586K 0.14% 118
2025
Q3 		– Sell
-521
Closed -$232K – 358
2025
Q2 		$232K Sell
521
-47
-8% -$21.7K 0.11% 205
2025
Q1 		$275K Buy
568
+46
+9% +$21.4K 0.17% 114
2024
Q4 		$210K Buy
522
+40
+8% +$18.5K 0.13% 128
2024
Q3 		$224K Buy
482
+12
+3% +$5.76K 0.15% 125
2024
Q2 		$220K Buy
+470
New +$204K 0.16% 113

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Abel Hall LLC's VRTX Position: Q2 2026 in Review

Abel Hall LLC reduced its Vertex Pharmaceuticals (VRTX) stake by 29% in Q2 2026, selling an estimated $188K and leaving 1,050 shares worth $522K. The position accounts for 0.09% of the portfolio, ranked #227.

Abel Hall LLC first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $658K in Q1 2026. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Abel Hall LLC held 1,050 shares of Vertex Pharmaceuticals worth $522K as of Q2 2026.
  • Abel Hall LLC sold 424 Vertex Pharmaceuticals shares in Q2 2026, an estimated $188K.
  • Vertex Pharmaceuticals made up 0.09% of Abel Hall LLC's portfolio in Q2 2026, its #227 holding.
  • Abel Hall LLC first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Abel Hall LLC's Vertex Pharmaceuticals position peaked at $658K in Q1 2026.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.